Table 4 The completed and recruiting clinical trials of EBV-associated GC

EBV⁺ GC/ENKTCL

EBViNT Cell

Phase 1

Phase 2

72

NCT03789617

RECRUITING

2018/12/14

−2024/12/01

https://clinicaltrials.gov/study/NCT03789617

EBV⁺ Advanced GC

Poripalimab⁺Oxaliplatin

Phase 2

30

NCT05970627

NOT YRT RECRUITING

2023/7/28

−2029/07/28

https://clinicaltrials.gov/study/NCT05970627

EBV⁺ GC

Pembrolizumab, Capecitabine, and Radiation Therapy

Phase 2

40

NCT03257163

RECRUITING

2017/9/29

−2025/12/31

https://clinicaltrials.gov/study/NCT03257163

EBV⁺ Refractory Malignant Tumors

mRNA vaccine

Phase 1

9

NCT05714748

RECRUITING

2022/11/18

−2025/01/01

https://clinicaltrials.gov/search?cond=NCT05714748

Advanced EBV⁺ Solid Tumors

Nanatinostat Plus Valganciclovir

Phase 1

Phase 2

130

NCT05166577

RECRUITING

2021/10/08

−2025/10/01

https://clinicaltrials.gov/search?cond=NCT05166577